Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 241 participants.
Also called NCT01087502
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 241 participants
- Registry
-
NCT01087502 -
2009-016971-31
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- Not reported
- Results first posted
- Countries
- United States, Australia, Canada, Finland, Israel, Japan, New Zealand, Slovakia, Sweden
- Registry status
- Completed
Technical summary
Registry record NCT01087502. Randomized; double masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2012-05 (actual). Results posted on 2013-10-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Glimepiride
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Linagliptin
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01087502- Content hash
ce36eea334f073684e77023bd93844142a1ed1f79f17b33e5b140e5e74deb2f8